Tumor burden is predictive of survival in patients with non–small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib
Background Although activating epidermal growth factor receptor (EGFR) mutations are
excellent predictors of gefitinib outcome in non–small-cell lung cancer (NSCLC), most …
excellent predictors of gefitinib outcome in non–small-cell lung cancer (NSCLC), most …
Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib …
Purpose To explore predictive factors for time to treatment failure (TTF) in chemotherapy-
naive non–small-cell lung cancer (NSCLC) patients receiving gefitinib treatment. Patients …
naive non–small-cell lung cancer (NSCLC) patients receiving gefitinib treatment. Patients …
Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North …
C Ho, N Murray, J Laskin, B Melosky, H Anderson… - Lung Cancer, 2005 - Elsevier
Institutional series suggest specific subgroups of patients with non-small cell lung cancer
(NSCLC); female, Asian, non-smokers, respond preferentially to gefitinib. Vancouver, BC …
(NSCLC); female, Asian, non-smokers, respond preferentially to gefitinib. Vancouver, BC …
Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib
Purpose This study was undertaken to investigate the effects of epidermal growth factor
receptor (EGFR) mutation and its downstream signaling on response and survival in non …
receptor (EGFR) mutation and its downstream signaling on response and survival in non …
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
S Kakiuchi, Y Daigo, N Ishikawa… - Human Molecular …, 2004 - academic.oup.com
Abstract Gefitinib (Iressa, ZD1839), an inhibitor of epidermal growth factor receptor-tyrosine
kinase, has shown potent anti-tumor effects and improved symptoms and quality-of-life of a …
kinase, has shown potent anti-tumor effects and improved symptoms and quality-of-life of a …
[PDF][PDF] Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer
Introduction 2.1. EGFR pathway 2.2. EGFR targeted therapy 2.2. 1. Tyrosine kinase
inhibitors (TKIs) 2.2. 2. Monoclonal antibodies 3. Polymorphisms 3.1. Polymorphisms …
inhibitors (TKIs) 2.2. 2. Monoclonal antibodies 3. Polymorphisms 3.1. Polymorphisms …
[HTML][HTML] Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative …
JM Amann, JW Lee, H Roder, J Brahmer… - Journal of Thoracic …, 2010 - Elsevier
Introduction Serum proteomics and mutations in the epidermal growth factor receptor
(EGFR) and KRAS have been associated with benefit after therapy with EGFR-targeted …
(EGFR) and KRAS have been associated with benefit after therapy with EGFR-targeted …
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
AA Armour, CL Watkins - European Respiratory Review, 2010 - Eur Respiratory Soc
As the first approved epidermal growth factor receptor (EGFR)-targeted therapy for nonsmall
cell lung cancer (NSCLC), the clinical development of gefitinib was complex. Advances in …
cell lung cancer (NSCLC), the clinical development of gefitinib was complex. Advances in …
[HTML][HTML] Identification of hub genes and small molecule drugs associated with acquired resistance to gefitinib in non-small cell lung cancer
G Li, Y Ma, M Yu, X Li, X Chen, Y Gao, P Cheng… - Journal of …, 2021 - ncbi.nlm.nih.gov
Targeting EGFR, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs),
brings lights to the treatment of non-small cell lung cancer (NSCLC). Although T790M …
brings lights to the treatment of non-small cell lung cancer (NSCLC). Although T790M …
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non–small-cell lung cancer
VA Miller, MG Kris, N Shah, J Patel, C Azzoli… - Journal of Clinical …, 2004 - ascopubs.org
Purpose Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase,
induces radiographic regressions and symptomatic improvement in patients with non–small …
induces radiographic regressions and symptomatic improvement in patients with non–small …